METHOD OF EVALUATION OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN BASED ON EXPRESSION LEVELS OF MARKER GENES AND SET FOR ITS IMPLEMENTATION Russian patent published in 2014 - IPC C12Q1/68 C12N15/11 

FIELD: biotechnology.

SUBSTANCE: method is based on comparison of the expression levels of the marker genes ABCC1, ERCC1, FTL, GSTP1, MT2A, RRM1, TUBB3 in the cells under study with the expression levels of the said genes in the control cells of NCI-H322. The method comprises hybridisation of fluorescently labelled nucleic acid preparations prepared from human cells or tissues with a data array of oligonucleotide probes immobilised on a solid substrate. The substrate is washed from nonspecifically bound preparations. The substrate is scanned by a laser scanner and the resulting image is analysed. When increased expression of genes ERCC1, MT2A, RRM1 and TUBB3 and reduced expression of genes AVSS1, GSTP1, FTL in the cells under study relative to cells NCI-H322, IC50 of doxorubicin for the cells under study is evaluated at the level IC50≥0.54 mcM, and the cells are considered to be stable. At reduced expression of genes ERCC1, MT2A, RRM1 and TUBB3 and increased expression of genes AVSS1, GSTP1, FTL in the cells under study relative to the cells NCI-H322, IC50 of doxorubicin for the cells under study is evaluated at the level IC50≤0.073 mcM, and the cells are considered to be sensitive.

EFFECT: invention enables to determine the sensitivity of lung cancer cells to doxorubicin with high accuracy.

2 cl, 1 dwg, 1 tbl, 2 ex